Cas:54932-77-3 2,5-di(butan-2-yl)phenol manufacturer & supplier

We serve Chemical Name:2,5-di(butan-2-yl)phenol CAS:54932-77-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2,5-di(butan-2-yl)phenol

Chemical Name:2,5-di(butan-2-yl)phenol
CAS.NO:54932-77-3
Synonyms:Phenol,2,5-bis(1-methylpropyl);2,5-Disec-butylphenol;2,5-Bis(1-methylpropyl)phenol
Molecular Formula:C14H22O
Molecular Weight:206.32400
HS Code:2907199090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:298.2ºC at 760 mmHg
Density:0.933g/cm3
Index of Refraction:1.506
PSA:20.23000
Exact Mass:206.16700
LogP:4.41920

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Phenol,2,5-bis(1-methylpropyl) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,5-Bis(1-methylpropyl)phenol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,5-Disec-butylphenol Use and application,Phenol,2,5-bis(1-methylpropyl) technical grade,usp/ep/jp grade.


Related News: Other innovative technology developments have made immobilizing enzymes on solid supports like glass, silicon, or any other polymer more efficient. 3-(Chloromethyl)-2-hydroxy-5-methylbenzaldehyde manufacturers GBS is a rare but potentially life-threatening disorder in which the body’s immune system attacks nerve cells. The condition has been associated with the use of other widely used vaccines, such as GlaxoSmithKline’s Shingrix. 1-(4-pyren-1-ylbutanoyl)pyrrolidine-2,5-dione suppliers Other innovative technology developments have made immobilizing enzymes on solid supports like glass, silicon, or any other polymer more efficient. 1-[(5,6-Dimethyl-2-methoxypyrazin-3-yl)aminocarbonyl]-4-(3,5-dinitrophenyl)piperazine vendor & factory Except current data is insufficient to determine its benefit in patients who are negative for anti-AChR antibodies.,Except current data is insufficient to determine its benefit in patients who are negative for anti-AChR antibodies.